- Home
- WVE vs GRAL Comparison
WVE vs GRAL Comparison
Compare WVE & GRAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVE
- GRAL
- Stock Information
- Founded
- WVE 2012
- GRAL 2016
- Country
- WVE Singapore
- GRAL United States
- Employees
- WVE N/A
- GRAL N/A
- Industry
- WVE Biotechnology: Pharmaceutical Preparations
- GRAL
- Sector
- WVE Health Care
- GRAL
- Exchange
- WVE Nasdaq
- GRAL NYSE
- Market Cap
- WVE 1.7B
- GRAL 1.8B
- IPO Year
- WVE 2015
- GRAL N/A
- Fundamental
- Price
- WVE $7.77
- GRAL $24.90
- Analyst Decision
- WVE Strong Buy
- GRAL Hold
- Analyst Count
- WVE 11
- GRAL 2
- Target Price
- WVE $22.00
- GRAL $20.00
- AVG Volume (30 Days)
- WVE 1.3M
- GRAL 1.3M
- Earning Date
- WVE 03-04-2025
- GRAL 05-15-2025
- Dividend Yield
- WVE N/A
- GRAL N/A
- EPS Growth
- WVE N/A
- GRAL N/A
- EPS
- WVE N/A
- GRAL N/A
- Revenue
- WVE $108,302,000.00
- GRAL $125,595,000.00
- Revenue This Year
- WVE N/A
- GRAL $24.65
- Revenue Next Year
- WVE $33.28
- GRAL $12.88
- P/E Ratio
- WVE N/A
- GRAL N/A
- Revenue Growth
- WVE N/A
- GRAL 34.90
- 52 Week Low
- WVE $4.25
- GRAL $12.33
- 52 Week High
- WVE $16.74
- GRAL $63.99
- Technical
- Relative Strength Index (RSI)
- WVE 31.26
- GRAL N/A
- Support Level
- WVE $9.43
- GRAL N/A
- Resistance Level
- WVE $10.91
- GRAL N/A
- Average True Range (ATR)
- WVE 0.61
- GRAL 0.00
- MACD
- WVE -0.18
- GRAL 0.00
- Stochastic Oscillator
- WVE 0.00
- GRAL 0.00
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
About GRAL GRAIL INC
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages.